IN2012DN02610A - - Google Patents

Download PDF

Info

Publication number
IN2012DN02610A
IN2012DN02610A IN2610DEN2012A IN2012DN02610A IN 2012DN02610 A IN2012DN02610 A IN 2012DN02610A IN 2610DEN2012 A IN2610DEN2012 A IN 2610DEN2012A IN 2012DN02610 A IN2012DN02610 A IN 2012DN02610A
Authority
IN
India
Prior art keywords
compound
Prior art date
Application number
Other languages
English (en)
Inventor
Casebier David
P Robinson Simon
Purohit Ajay
S Radeke Heike
T Azure Michael
D Dischino Douglas
Original Assignee
Bristol Myers Squibb Pharma Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Pharma Co filed Critical Bristol Myers Squibb Pharma Co
Publication of IN2012DN02610A publication Critical patent/IN2012DN02610A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/14—Oxygen atoms
    • C07D237/16—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0052—Small organic molecules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/0412—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K51/0421—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Acoustics & Sound (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Nuclear Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
IN2610DEN2012 2004-02-13 2005-02-11 IN2012DN02610A (en:Method)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US54486104P 2004-02-13 2004-02-13
US11/055,498 US7344702B2 (en) 2004-02-13 2005-02-10 Contrast agents for myocardial perfusion imaging
PCT/US2005/004687 WO2005079391A2 (en) 2004-02-13 2005-02-11 Contrast agents for myocardial perfusion imaging

Publications (1)

Publication Number Publication Date
IN2012DN02610A true IN2012DN02610A (en:Method) 2015-09-04

Family

ID=34889838

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2610DEN2012 IN2012DN02610A (en:Method) 2004-02-13 2005-02-11

Country Status (18)

Country Link
US (7) US7344702B2 (en:Method)
EP (2) EP3385253B1 (en:Method)
JP (3) JP5417578B2 (en:Method)
KR (2) KR101186449B1 (en:Method)
CN (2) CN102274527B (en:Method)
AU (1) AU2005214898C1 (en:Method)
BR (1) BRPI0507684B8 (en:Method)
CA (3) CA2556213C (en:Method)
DK (2) DK1713512T3 (en:Method)
ES (2) ES2878171T3 (en:Method)
IL (4) IL177275A0 (en:Method)
IN (1) IN2012DN02610A (en:Method)
MX (1) MX348859B (en:Method)
NO (2) NO344857B1 (en:Method)
PT (1) PT1713512T (en:Method)
RU (2) RU2457865C2 (en:Method)
SG (1) SG149895A1 (en:Method)
WO (1) WO2005079391A2 (en:Method)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7344702B2 (en) * 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
US7485283B2 (en) * 2004-04-28 2009-02-03 Lantheus Medical Imaging Contrast agents for myocardial perfusion imaging
US7824659B2 (en) * 2005-08-10 2010-11-02 Lantheus Medical Imaging, Inc. Methods of making radiolabeled tracers and precursors thereof
CA2625196C (fr) * 2005-10-07 2016-04-05 Guerbet Composes comprenant une partie de reconnaissance d'une cible biologique, couplee a une partie de signal capable de complexer le gallium
US8986650B2 (en) 2005-10-07 2015-03-24 Guerbet Complex folate-NOTA-Ga68
US8673929B2 (en) * 2006-07-20 2014-03-18 Gilead Sciences, Inc. 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections
WO2008009078A2 (en) 2006-07-20 2008-01-24 Gilead Sciences, Inc. 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections
EP2474526A3 (en) 2006-12-26 2012-07-25 Lantheus Medical Imaging, Inc. Ligands for imaging cardiac innervation
WO2008128058A1 (en) * 2007-04-13 2008-10-23 The Trustees Of The University Of Pennsylvania New gallium bisaminothiolate complexes for myocardial imaging
PT2257315T (pt) * 2008-02-29 2020-01-27 Lantheus Medical Imaging Inc Agentes de contraste para aplicações incluindo imagiologia de perfusão
AU2015200027B2 (en) * 2008-02-29 2017-01-19 Lantheus Medical Imaging, Inc. Contrast agents for applications including perfusion imaging
BRPI0910525A2 (pt) * 2008-07-09 2015-09-29 Koninkl Philips Electronics Nv agente de contraste para a formação de imagem f19 mri e nuclear concomitantes, aparelho de diagnóstico de imagem para imagem de contraste realçado, método de diagnostico por imagem, processador programado para controlador um scanner híbrido de ressonância magnética e tomografia de emissão de pósitron, software que contém midia que pode ser lida por computador, e, aparelho de formação de imagem médica para a geração de imagens realçadas de contraste.
KR101602992B1 (ko) * 2009-04-15 2016-03-11 랜티우스 메디컬 이메징, 인크. 아스코르브산을 사용한 방사성 약제 조성물의 안정화
US20120238740A1 (en) * 2009-07-11 2012-09-20 Bayer Pharma Aktiengesellschaft Non-polar and polar leaving groups
EP2289889A1 (en) * 2009-08-18 2011-03-02 Endura S.p.a. Substituted alkynyl phenoxy compounds and their uses
CN101993383A (zh) * 2009-08-26 2011-03-30 成都伊诺达博医药科技有限公司 决奈达隆关键中间体4-[3-(二丁氨基)丙氧基]苯甲酸甲酯的新合成方法
EP4046990A1 (en) * 2010-02-08 2022-08-24 Lantheus Medical Imaging, Inc. Methods and apparatus for synthesizing imaging agents, and intermediates thereof
KR102008635B1 (ko) 2010-05-11 2019-08-07 랜티우스 메디컬 이메징, 인크. 영상화제의 합성 및 사용을 위한 조성물, 방법 및 시스템
CN102038964B (zh) * 2010-12-30 2012-01-25 上海师范大学 一种非晶态铁钴硼纳米磁共振造影剂材料及其制备方法
BR122019017259B1 (pt) 2011-09-09 2022-05-10 Lantheus Medical Imaging, Inc Compostos úteis como agentes de imageamento, composições que os compreende, métodos, e uso de agentes de imageamento
CA2852395C (en) * 2011-10-21 2020-04-28 Lantheus Medical Imaging, Inc. Compositions comprising ascorbic acid and pyridaben and pyridaben analogs attached to an imaging moiety and related methods
KR101931792B1 (ko) * 2011-12-22 2019-03-13 레스피라토리우스 아브 심근 관류를 영상화하기 위한 조영제
SG11201406206RA (en) 2012-04-10 2014-10-30 Lantheus Medical Imaging Inc Radiopharmaceutical synthesis methods
AU2013203000B9 (en) * 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
WO2014030709A1 (ja) 2012-08-24 2014-02-27 浜松ホトニクス株式会社 ミトコンドリアＣｏｍｐｌｅｘ－１の検出に適した化合物
CN105849094B (zh) * 2013-12-26 2018-04-10 住友化学株式会社 卤素取代苯酞的制造方法
US9745308B2 (en) 2014-09-12 2017-08-29 Chiesi Farmaceutici S.P.A. Pyridazinone derivatives as phoshoinositide 3-kinases inhibitors
PH12021551982A1 (en) 2015-03-04 2022-09-05 Gilead Sciences Inc Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
EP3507276B1 (en) 2016-09-02 2021-11-03 Gilead Sciences, Inc. Toll like receptor modulator compounds
WO2018045150A1 (en) 2016-09-02 2018-03-08 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
EP3594200B1 (en) * 2017-03-07 2022-03-02 Nihon Medi-Physics Co., Ltd. Radioactive fluorine-labeled precursor compound, and method for producing radioactive fluorine-labeled compound using same
TW202212339A (zh) 2019-04-17 2022-04-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751516B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI879779B (zh) 2019-06-28 2025-04-11 美商基利科學股份有限公司 類鐸受體調節劑化合物的製備方法
GB201915206D0 (en) 2019-10-21 2019-12-04 Ge Healthcare Ltd Use of cyclodextrins as a radiostabilizer
CN111320620A (zh) * 2020-03-17 2020-06-23 四川大学华西医院 一种异喹啉并哒嗪酮类化合物及其合成方法和应用
CN116082670B (zh) * 2023-04-11 2023-06-27 中国人民解放军军事科学院军事医学研究院 一种含有季膦盐的声响应假性共轭聚合物纳米颗粒的制备方法及其在抗菌领域的应用

Family Cites Families (122)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1073999A (en) 1965-01-29 1967-06-28 Ncr Co Process for forming stable images in photochromic material
JPS5888334A (ja) * 1981-11-20 1983-05-26 Takasago Corp ３−ｌ−メントキシプロパン−１、２−ジオ−ル
US4510125A (en) 1982-12-08 1985-04-09 Mallinckrodt, Inc. Process for making lyophilized radiographic imaging kit
JPS604173A (ja) 1983-06-23 1985-01-10 Nissan Chem Ind Ltd ピリダジノン誘導体，その製造法および殺虫・殺ダニ・殺菌剤
EP0169375B1 (en) 1984-06-23 1989-12-20 Nissan Chemical Industries Ltd. Process for producing 2-tert.-butyl-4,5-dichloro-3(2h)-pyridazinone
JPH07116161B2 (ja) 1984-07-04 1995-12-13 日産化学工業株式会社 ピリダジノン誘導体
JPS61130275A (ja) 1984-11-29 1986-06-18 Nissan Chem Ind Ltd ピリダジノン誘導体，その製造法および殺虫・殺ダニ・殺菌剤
EP0183212B1 (en) 1984-11-29 1990-06-20 Nissan Chemical Industries Ltd. Pyridazinone derivatives, preparation thereof, and insecticidal, acaricidal, nematicidal, fungicidal compositions
CA1265798A (en) 1984-12-10 1990-02-13 Motoo Mutsukado 3(2h)pyridazinone, process for its preparation and anti-allergic agent containing it
US5393512A (en) 1985-01-14 1995-02-28 Vanderheyden; Jean-Luc Stable therapeutic radionuclide compositions and methods for preparation thereof
JPH0641454B2 (ja) 1985-02-27 1994-06-01 日産化学工業株式会社 ピリダジノン誘導体
JPS61260018A (ja) 1985-05-14 1986-11-18 Nissan Chem Ind Ltd 抗アレルギ−剤
TR22638A (tr) 1985-07-30 1988-01-29 Nissan Chemical Ind Ltd Piridazinon tuerevleri,bunlarin ve hasarat oeldueruecue bilesiklerin hazirlanmasina mahsus usul
JPH0739397B2 (ja) 1985-07-30 1995-05-01 日産化学工業株式会社 ピリダジノン誘導体および害虫防除剤
JPH07110815B2 (ja) 1985-11-18 1995-11-29 ボ−ド・オブ・リ−ジェンツ、ザ・ユニバ−シティ−・オブ・テキサス・システム 画像及びスペクトル向上（およびスペクトルシフト）のためのポリキレ−ト剤
JPS6315974A (ja) 1986-07-09 1988-01-23 小泉コンピユ−タ−株式会社 ボ−リングゲ−ム点数表表示装置
US5567411A (en) 1986-11-10 1996-10-22 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Dendritic amplifier molecules having multiple terminal active groups stemming from a benzyl core group
US5252317A (en) 1986-11-10 1993-10-12 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Amplifier molecules for diagnosis and therapy derived from 3,5-bis[1-(3-amino-2,2-bis (aminomethyl)-propyl) oxymethyl] benzoic acid
JPS63159374A (ja) 1986-12-24 1988-07-02 Nissan Chem Ind Ltd ピリダジノン誘導体および殺虫、殺ダニ、殺線虫剤
JPS63159372A (ja) 1986-12-24 1988-07-02 Nissan Chem Ind Ltd ピリダジノン化合物および殺虫、殺ダニ、殺線虫剤
JPS63159373A (ja) 1986-12-24 1988-07-02 Nissan Chem Ind Ltd ピリダジノン類および殺虫、殺ダニ、殺線虫剤
DE3824210A1 (de) 1988-07-16 1990-01-18 Basf Ag 3(2h)-pyridazinonderivate zur bekaempfung von schnecken
IT1229684B (it) * 1989-04-05 1991-09-06 Mini Ricerca Scient Tecnolog Piridazinoni ad attivita' insetticida ed acaricida
JPH02279676A (ja) 1989-04-19 1990-11-15 Otsuka Chem Co Ltd ピリダジノン誘導体
US5087440A (en) 1989-07-31 1992-02-11 Salutar, Inc. Heterocyclic derivatives of DTPA used for magnetic resonance imaging
GB8923843D0 (en) 1989-10-23 1989-12-13 Salutar Inc Compounds
US5377681A (en) 1989-11-13 1995-01-03 University Of Florida Method of diagnosing impaired blood flow
US5088499A (en) 1989-12-22 1992-02-18 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5228446A (en) 1989-12-22 1993-07-20 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5679810A (en) 1990-01-19 1997-10-21 Salutar, Inc. Linear oligomeric polychelant compounds
JPH03220177A (ja) 1990-01-25 1991-09-27 Nissan Chem Ind Ltd 殺虫、殺ダニ剤組成物
US5250283A (en) * 1990-03-28 1993-10-05 Molecular Biosystems, Inc. Organic contrast agent analog and method of making same
WO1992017215A1 (en) 1990-03-28 1992-10-15 Nycomed Salutar, Inc. Contrast media
GB9006977D0 (en) 1990-03-28 1990-05-23 Nycomed As Compositions
JPH04235975A (ja) 1991-01-21 1992-08-25 Nissan Chem Ind Ltd ピリダジノン誘導体および害虫防除剤
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5306482A (en) 1991-04-09 1994-04-26 Merck Frosst Canada, Inc. Radiopharmaceutical bacteriostats
US5093105A (en) 1991-04-09 1992-03-03 Merck Frosst Canada, Inc. Radiopharmaceutical bacteriostats
JP3853354B2 (ja) 1991-08-29 2006-12-06 マリンクロッド・インコーポレイテッド 放射性標識ペプチドおよびタンパク質の自己放射線分解を防止する安定剤
US5169942A (en) 1991-11-21 1992-12-08 General Electric Company Method for making 2-(18F)fluoro-2-deoxy-D-glucose
ATE156997T1 (de) * 1992-06-17 1997-09-15 Procter & Gamble Nichtstechende zusammensetzungen mit kühleffekt
WO1994012479A1 (en) 1992-12-03 1994-06-09 Otsuka Kagaku Kabushiki Kaisha Pyridazinone derivative and insecticidal and miticidal agent
US5760191A (en) 1993-02-05 1998-06-02 Nycomed Imaging As Macrocyclic complexing agents and targeting immunoreagents useful in therapeutic and diagnostic compositions and methods
WO1994021653A1 (en) 1993-03-22 1994-09-29 General Electric Company Method for making 2-fluoro-2-deoxyglucose
MXPA94002323A (es) 1993-03-31 2002-06-18 Mallinckrodt Medical Inc Formulaciones radiofarmaceuticas que tienen reductores no estanosos.
US5417959A (en) 1993-10-04 1995-05-23 Mallinckrodt Medical, Inc. Functionalized aza-crytand ligands for diagnostic imaging applications
US5493026A (en) 1993-10-25 1996-02-20 Organix, Inc. Substituted 2-carboxyalkyl-3-(fluorophenyl)-8-(3-halopropen-2-yl) nortropanes and their use as imaging for agents for neurodegenerative disorders
GB9323028D0 (en) 1993-11-09 1994-01-05 Isis Innovation Asymmetric hydroboration
EP0665223A1 (en) 1994-01-28 1995-08-02 Takeda Chemical Industries, Ltd. Antitumor agent, novel 3(2H)-pyridazinone derivatives and their preparation
JPH07252236A (ja) 1994-01-28 1995-10-03 Takeda Chem Ind Ltd 抗癌剤
JPH10501218A (ja) 1994-06-03 1998-02-03 マリンクロッド・メディカル・インコーポレイテッド 迅速に消失するテクネチウム−９９ｍホスホネート骨格イメージング剤
US5520904A (en) 1995-01-27 1996-05-28 Mallinckrodt Medical, Inc. Calcium/oxyanion-containing particles with a polymerical alkoxy coating for use in medical diagnostic imaging
EP0727225A3 (en) 1995-02-14 1997-01-15 Sonus Pharma Inc Compositions and methods for directed ultrasonic imaging
US5587491A (en) 1995-03-15 1996-12-24 Regents Of The University Of Minnesota Method for the synthesis of bis-tetrahydrofuranyl Annonaceous acetogenins
US5801228A (en) 1995-06-07 1998-09-01 Nycomed Imaging As Polymeric contrast agents for medical imaging
US5811073A (en) 1995-06-19 1998-09-22 President And Fellows Of Harvard College Method for radioisotopic detection and localization of inflammation in a host
US5827073A (en) * 1995-07-05 1998-10-27 Ludwig Institute For Cancer Research Photoreactive peptide derivatives
US6066309A (en) 1996-02-02 2000-05-23 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
US5804161A (en) 1996-05-14 1998-09-08 Nycomed Salutar Inc. Contrast agents
US5846517A (en) 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
WO1998018497A2 (en) * 1996-10-28 1998-05-07 Nycomed Imaging As Contrast agents
US6565889B2 (en) 1996-12-02 2003-05-20 The Regents Of The University Of California Bilayer structure which encapsulates multiple containment units and uses thereof
US5961955A (en) 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
JP4017758B2 (ja) * 1998-08-04 2007-12-05 高砂香料工業株式会社 冷感剤組成物
US6056939A (en) 1998-08-28 2000-05-02 Desreux; Jean F. Self-assembling heteropolymetallic chelates as imaging agents and radiopharmaceuticals
WO2000018403A1 (en) * 1998-09-29 2000-04-06 Merck & Co., Inc. Radiolabeled neurokinin-1 receptor antagonists
US6645508B1 (en) 1999-06-18 2003-11-11 Jivn-Ren Chen Stable L-ascorbic acid composition
AU2001261728A1 (en) * 2000-05-17 2001-11-26 Bristol-Myers Squibb Pharma Company Use of small molecule radioligands for diagnostic imaging
GB0019357D0 (en) 2000-08-07 2000-09-27 Melacure Therapeutics Ab Novel phenyl guanidines
WO2002020008A1 (en) 2000-09-06 2002-03-14 The Scripps Research Institute Inhibitors of nadh:ubiquinone oxidoreductase
TWI247609B (en) 2001-01-23 2006-01-21 Nihon Mediphysics Co Ltd Agent for diagnosis of tissue proliferation activity or the treatment of proliferative disease
GB0115927D0 (en) 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase nucleophilic fluorination
US7344702B2 (en) 2004-02-13 2008-03-18 Bristol-Myers Squibb Pharma Company Contrast agents for myocardial perfusion imaging
US20030044354A1 (en) 2001-08-16 2003-03-06 Carpenter Alan P. Gas microsphere liposome composites for ultrasound imaging and ultrasound stimulated drug release
US20030082191A1 (en) 2001-08-29 2003-05-01 Poduslo Joseph F. Treatment for central nervous system disorders
US20050009730A1 (en) 2001-10-16 2005-01-13 Dale Edgar Treatment of cns disorders using cns target modulators
TWI266634B (en) 2002-02-06 2006-11-21 Univ Johns Hopkins Non-invasive diagnostic imaging technology for mitochondria dysfunction using radiolabeled lipophilic salts
JP4573533B2 (ja) * 2002-03-29 2010-11-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 放射能標識付きキノリンおよびキノリノン誘導体および代謝向性グルタメート受容体リガンドとしてのそれらの使用
WO2003086476A1 (en) 2002-04-08 2003-10-23 Biostream, Inc. Technetium-labeled rotenone derivatives, and methods of use thereof
GB0229683D0 (en) 2002-12-20 2003-01-29 Imaging Res Solutions Ltd Preparation of radiopharmaceuticals
WO2005003100A2 (en) * 2003-07-03 2005-01-13 Myriad Genetics, Inc. 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
WO2005007632A1 (en) 2003-07-18 2005-01-27 Pharmacia Corporation Substituted pyridazinones as inhibitors of p38
SG177216A1 (en) 2003-07-24 2012-01-30 Bracco Imaging Spa Stable radiopharmaceutical compositions and methods for their preparation
GB0317920D0 (en) 2003-07-31 2003-09-03 Amersham Plc Solid-phase synthesis
US7927616B2 (en) * 2004-01-16 2011-04-19 Thomas T. Yamashita Pesticide compositions and methods for their use
CA2552356C (en) 2004-02-24 2013-11-19 The General Hospital Corporation Catalytic radiofluorination
CA2558272C (en) 2004-03-05 2011-02-15 Banyu Pharmaceutical Co., Ltd. Pyridone derivative
AT500838B1 (de) 2004-04-20 2007-11-15 Veterinaermedizinische Uni Wie Multiple hse
US7485283B2 (en) 2004-04-28 2009-02-03 Lantheus Medical Imaging Contrast agents for myocardial perfusion imaging
US20060083681A1 (en) 2004-10-18 2006-04-20 Ajay Purohit Compounds for myocardial perfusion imaging
US7534418B2 (en) * 2004-12-10 2009-05-19 The Regents Of The University Of Michigan Imaging agents
KR100789847B1 (ko) 2004-12-15 2007-12-28 (주)퓨쳐켐 알코올 용매하에서 유기플루오로 화합물의 제조방법
US7837982B2 (en) 2005-06-23 2010-11-23 Emory University Imaging agents
US7824659B2 (en) 2005-08-10 2010-11-02 Lantheus Medical Imaging, Inc. Methods of making radiolabeled tracers and precursors thereof
JP2007112725A (ja) 2005-10-18 2007-05-10 Inst Nuclear Energy Research Rocaec 無支持体の１８Ｆで標識したアミノ酸Ｏ−（２−［１８Ｆ］ｆｌｕｏｒｏｅｔｈｙｌ）−Ｌ−Ｔｙｒｏｓｉｎｅの製造方法。
US7871623B2 (en) 2005-12-21 2011-01-18 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for imaging pain and stress in vivo
WO2008118122A2 (en) 2006-05-08 2008-10-02 Molecular Neuroimaging, Llc Compounds and amyloid probes thereof for therapeutic and imaging uses
MX2008016344A (es) 2006-06-21 2009-02-12 Ge Healthcare Ltd Productos radiofarmaceuticos.
CN101506195A (zh) 2006-08-25 2009-08-12 贝林格尔.英格海姆国际有限公司 具有mch拮抗活性的新颖吡啶酮衍生物及包含这些化合物的药物
GB0625523D0 (en) 2006-12-21 2007-01-31 Ge Healthcare Ltd In vivo imaging agents
EP2474526A3 (en) 2006-12-26 2012-07-25 Lantheus Medical Imaging, Inc. Ligands for imaging cardiac innervation
JP5504563B2 (ja) 2006-12-27 2014-05-28 住友化学株式会社 組成物及び該組成物を用いてなる発光素子
GB0718386D0 (en) 2007-09-21 2007-10-31 Ge Healthcare As Improved radiopharmaceutical formulation
KR101068835B1 (ko) 2007-10-26 2011-09-30 한국과학기술연구원 베타-아밀로이드 집적체 및 피브릴에 우수한 결합 친화도를가지는 이소인돌론 화합물 및 이의 제조 방법
CL2008003785A1 (es) 2007-12-21 2009-10-09 Du Pont Compuestos derivados de piridazina; composiciones herbicidas que comprenden a dichos compuestos; y método para controlar el crecimiento de la vegetación indeseada.
WO2009103478A1 (en) 2008-02-19 2009-08-27 Boehringer Ingelheim International Gmbh Pyridone and pyridazinone derivatives as mch antagonists
WO2010011367A2 (en) 2008-02-22 2010-01-28 Illinois Institute Of Technology Bimodal ligands with macrocyclic and acyclic binding moieties, complexes and compositions thereof, and methods of using
PT2257315T (pt) 2008-02-29 2020-01-27 Lantheus Medical Imaging Inc Agentes de contraste para aplicações incluindo imagiologia de perfusão
US8258134B2 (en) 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
US8278316B2 (en) 2009-03-09 2012-10-02 Bristol-Myers Squibb Company Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists
KR101602992B1 (ko) 2009-04-15 2016-03-11 랜티우스 메디컬 이메징, 인크. 아스코르브산을 사용한 방사성 약제 조성물의 안정화
CN101555232B (zh) 2009-05-21 2011-01-05 北京师范大学 氟-18标记哒嗪酮类化合物及制备方法和应用
US20120238740A1 (en) 2009-07-11 2012-09-20 Bayer Pharma Aktiengesellschaft Non-polar and polar leaving groups
EP4046990A1 (en) 2010-02-08 2022-08-24 Lantheus Medical Imaging, Inc. Methods and apparatus for synthesizing imaging agents, and intermediates thereof
DE102010036356A1 (de) 2010-07-12 2012-01-12 Abx Advanced Biochemical Compounds Gmbh Vorrichtung zur Synthese radioaktiv markierter Verbindungen
JP5842594B2 (ja) 2010-12-27 2016-01-13 住友化学株式会社 ピリダジノン化合物、それを含有する除草剤及び有害節足動物防除剤
CN102336741B (zh) 2011-07-06 2013-04-10 北京师范大学 氟-18标记的心肌灌注显像剂及其制备方法和应用
BR122019017259B1 (pt) 2011-09-09 2022-05-10 Lantheus Medical Imaging, Inc Compostos úteis como agentes de imageamento, composições que os compreende, métodos, e uso de agentes de imageamento
CA2852395C (en) 2011-10-21 2020-04-28 Lantheus Medical Imaging, Inc. Compositions comprising ascorbic acid and pyridaben and pyridaben analogs attached to an imaging moiety and related methods
AU2013203000B9 (en) 2012-08-10 2017-02-02 Lantheus Medical Imaging, Inc. Compositions, methods, and systems for the synthesis and use of imaging agents
KR102290407B1 (ko) 2012-08-13 2021-08-19 더 제너럴 하스피탈 코포레이션 미토콘드리아 복합체 1의 정량적 맵핑을 위한 시스템 및 방법

Also Published As

Publication number Publication date
SG149895A1 (en) 2009-02-27
US20180009763A1 (en) 2018-01-11
WO2005079391A2 (en) 2005-09-01
MX348859B (es) 2017-06-30
AU2005214898C1 (en) 2011-08-04
US8226929B2 (en) 2012-07-24
BRPI0507684B8 (pt) 2021-07-27
EP1713512A4 (en) 2009-01-07
US7344702B2 (en) 2008-03-18
EP1713512A2 (en) 2006-10-25
IL177275A (en) 2013-11-28
US20210300878A1 (en) 2021-09-30
CA2828128A1 (en) 2005-09-01
IL177275A0 (en) 2006-12-10
AU2005214898A1 (en) 2005-09-01
CA2944947A1 (en) 2005-09-01
DK1713512T3 (en) 2018-04-23
US20120276006A1 (en) 2012-11-01
RU2012113613A (ru) 2013-10-20
RU2648358C2 (ru) 2018-03-23
CA2556213C (en) 2013-12-17
US20050191238A1 (en) 2005-09-01
US9718786B2 (en) 2017-08-01
IL243840A0 (en) 2016-04-21
NO20170638A1 (no) 2006-11-08
EP1713512B1 (en) 2018-01-10
CN1925878A (zh) 2007-03-07
JP2014218525A (ja) 2014-11-20
CA2556213A1 (en) 2005-09-01
RU2006132814A (ru) 2008-03-20
PT1713512T (pt) 2018-04-17
BRPI0507684A (pt) 2007-07-17
US10889550B2 (en) 2021-01-12
RU2457865C2 (ru) 2012-08-10
JP5417578B2 (ja) 2014-02-19
US10125106B2 (en) 2018-11-13
HK1164731A1 (en) 2012-09-28
EP3385253B1 (en) 2021-04-07
NO20064011L (no) 2006-11-08
KR20060122920A (ko) 2006-11-30
IL228097A0 (en) 2013-09-30
CN102274527B (zh) 2015-04-29
JP2007526916A (ja) 2007-09-20
BRPI0507684B1 (pt) 2021-02-23
KR101386851B1 (ko) 2014-04-17
US20160130235A1 (en) 2016-05-12
CA2828128C (en) 2016-11-22
JP6124848B2 (ja) 2017-05-10
EP3385253A1 (en) 2018-10-10
US20080112884A1 (en) 2008-05-15
NO344857B1 (no) 2020-06-02
KR20120031243A (ko) 2012-03-30
CN1925878B (zh) 2011-10-12
WO2005079391A3 (en) 2006-02-16
ES2878171T3 (es) 2021-11-18
KR101186449B1 (ko) 2012-09-27
AU2005214898B2 (en) 2011-01-06
US20190127333A1 (en) 2019-05-02
US9161997B2 (en) 2015-10-20
CN102274527A (zh) 2011-12-14
ES2665687T3 (es) 2018-04-26
IL228097A (en) 2016-02-29
JP2013047277A (ja) 2013-03-07
JP5847065B2 (ja) 2016-01-20
DK3385253T3 (da) 2021-06-28

Similar Documents

Publication Publication Date Title
IN2012DN02610A (en:Method)
IN2014CN03762A (en:Method)
IN2014CN03629A (en:Method)
IL181732A0 (en) 2-morpholino-4-pyrimidone compound
TW200617019A (en) A process for the preparation of 7α-alkylated 19-norsteroids
GB0415663D0 (en) Compound
IL177296A0 (en) Antithrombotic compound
GB0408771D0 (en) Compound
GB0427403D0 (en) Novel compounds I
GB0421106D0 (en) Compound
GB0414760D0 (en) The alternative
GB0411562D0 (en) Compound
GB0425969D0 (en) Compound
IN2014CN04215A (en:Method)
PL1674632T3 (pl) Gipsowa płyta budowlana
GB0428295D0 (en) Compound
MD2731B2 (en:Method)
GB0413764D0 (en) Novel compound
GB0413758D0 (en) Novel compound
GB0413769D0 (en) Novel compound
GB0413768D0 (en) Novel compound
GB0413766D0 (en) Novel compound
GB0413765D0 (en) Novel compound
GB0412551D0 (en) Novel compound
GB0412550D0 (en) Novel compound